Search Results
Your search for ,dUe matches 5584 pages
Showing 51 - 100Memorial Sloan Kettering Names Recipients of 2025 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) will award three cancer researchers with this year’s Paul Marks Prize for Cancer Research. The prize, named in honor of former MSK president Paul Marks, MD, recognizes a new generation of leaders who are making significant contributions to the...
Significant Medicare Physician Reimbursement Methodology Changes Finalized for 2026
The Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule final rule for 2026 on October 31, 2025.1 The rule finalizes physician reimbursement and policy reforms under the Physician Fee Schedule as well as changes to reporting requirements and policy...
Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC
With 10 years of follow-up, no significant difference in survival rates was reported between patients who were treated with stereotactic ablative radiotherapy (SABR) or video-assisted thoracoscopic surgery (VATS) for early-stage non–small cell lung cancer (NSCLC). These findings from the revised...
Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining) unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer,...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
European Society for Medical Oncology Congress 2025 Meeting Highlights
The European Society for Medical Oncology (ESMO) Congress 2025 in Berlin featured many important trials with the potential to significantly influence clinical practice and improve outcomes for patients with multiple tumor types. These studies highlighted the benefits of novel treatment combination...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved outcomes vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy. Results...
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women?
Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery...
New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets
Using a computational tool, DeepTarget, physicians were able to predict both primary and secondary targets of small-molecule agents for cancer treatment, according to findings from a study published in npj Precision Oncology. The study authors suggest that this represents a potentially significant...
FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas
On November 19, the U.S. Food and Drug Administration (FDA) approved selumetinib (Koselugo), a MEK inhibitor, for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). In September 2025, the FDA approved selumetinib capsules and granules for...
Quality Improvement Program Cuts Missed Radiation Appointments by 40%
A national quality improvement program led by the American College of Surgeons (ACS) found that transportation barriers and illness are among the top reasons patients with cancer miss critical radiation therapy appointments—and that providing hospitals and patients with structured support can...
Izalontamab Brengitecan in Recurrent or Metastatic Nasopharyngeal Carcinoma
In an interim analysis of a Chinese phase III trial (BL-B01D1-303) reported in The Lancet, Yang et al found that izalontamab brengitecan (iza-bren)—a bispecific antibody–drug conjugate targeting EGFR and HER3—significantly improved the objective response rate vs physician’s choice of chemotherapy...
Long-Term Continuous Nirogacestat in Adults With Desmoid Tumors
As reported in the Journal of Clinical Oncology by Ratan et al, long-term follow-up in the phase III DeFi trial has shown maintained benefits with prolonged nirogacestat treatment in patients with desmoid tumors. Study Details In the double-blind trial, 142 patients with progressing desmoid tumors...
Survey Highlights Unmet Needs Among Young Women With Advanced Breast Cancer
Almost half of all women (48%) under the age of 40 who are living with advanced breast cancer have children under the age of 18, and 64% of these young patients also experience employment disruptions after they are diagnosed, according to findings from a survey conducted by the Young Survival...
Reducing the Impact of Climate-Induced Events on Patients and Oncology Staff
Although 2023 made headlines as the hottest year in human history,1 drawing the world closer to breaching the goals outlined in the Paris Agreement to substantially reduce global greenhouse gas emissions to limit global warming to well below 2°C above preindustrial levels (and preferably to...
Safety and Benefit of Radiation Therapy for High-Risk Muscle-Invasive Bladder Cancer
Following cystectomy, patients with muscle-invasive bladder cancer at high risk for recurrence may safely be treated with radiotherapy and may achieve an improvement in locoregional control compared with observation. These findings, which come from the phase III BART trial presented in a plenary...
Hepatic Arterial Infusion Pump Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma
In a Dutch phase II trial (PUMP-2) reported in the Journal of Clinical Oncology, Franssen et al found that use of hepatic arterial infusion pump (HAIP) chemotherapy with floxuridine, with or without concomitant gemcitabine, plus cisplatin showed good activity and improved overall survival in...
New Report: Lung Cancer Advancements Are Saving More Lives Than Ever, but Funding Cuts May Hinder Progress
The American Lung Association has released its 2025 “State of Lung Cancer” report, which reveals great strides in efforts to end lung cancer—the leading cause of cancer-related deaths in the United States. This year, nearly 227,000 people in the United States will be diagnosed with lung cancer....
Diminishing the National Cancer Institute Threatens Americans
In an effort to reduce the size of government, the current administration has proposed an across the board 37% reduction1 in funding for the National Cancer Institute (NCI). This will result in approval of only 4% of applications2 from scientists at universities and cancer centers, with 96% of all ...
Zanzalintinib Plus Atezolizumab vs Regorafenib in Previously Treated Metastatic Colorectal Cancer Without MSI-H or dMMR Tumors
In a phase III trial (STELLAR-303) reported in The Lancet, Hecht et al found that the combination of the multitargeted tyrosine kinase inhibitor zanzalintinib and atezolizumab improved overall survival vs regorafenib in patients with previously treated relapsed or refractory metastatic colorectal...
Reflections of a Medical Oncologist: Empathy Matters in Caring for Patients With Cancer
“Someday you will be a doctor, Fazlur, and help people,” were the prophetic words of a mother to her son and the driving force behind the early quest of Fazlur Rahman, MD, to become a physician. Born and raised in what is now Bangladesh, he experienced the death of his mother at the young age of ...
Addition of Abemaciclib to Abiraterone in mCRPC
In a phase III study (CYCLONE 2) reported in The Lancet Oncology, Smith et al found that the addition of abemaciclib to abiraterone did not significantly improve radiographic progression–free survival in men with metastatic castration-resistant prostate cancer (mCRPC). Study Details In the...
Jobs Commonly Held by Immigrant Women May Put Them at Increased Risk for Breast Cancer
Many immigrant women in the United States work in jobs that may expose them to chemicals linked to breast cancer, according to a recent study led by Silent Spring Institute. The analysis is among the first to examine how job-related chemical exposures may contribute to breast cancer risk among...
Global Analysis Uncovers Wide Inequalities in Care for Breast, Cervical, and Ovarian Cancers
A major study of three of the most common cancers in women, conducted by the Cancer Survival Group at the London School of Hygiene & Tropical Medicine, found variations in the stage of disease at diagnosis, the type of treatment, and the extent to which treatment was consistent with...
Preneoplastic and Neoplastic Small Lymphocytic Proliferations
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the key epidemiologic, pathologic, diagnostic, and prognostic aspects of chronic...
Zenocutuzumab Potential Explored in NRG1-Positive Cholangiocarcinoma
Zenocutuzumab-zbco yielded clinical activity in more than one-third of patients with cholangiocarcinoma and an NRG1 fusion, according to findings from the phase II eNRGy trial presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Abstract ...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
Sacituzumab Tirumotecan in EGFR-Mutated Advanced NSCLC
In a Chinese phase III trial (OptiTROP-Lung-04) reported at the recent ESMO Congress and published in The New England Journal of Medicine, Fang et al found that monotherapy with sacituzumab tirumotecan (sac-TMT)—an antibody-drug conjugate targeting trophoblast cell–surface antigen 2—was associated...
Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved outcomes vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy. Results...
Defying the Odds
In early 2023, I began experiencing serious symptoms that were not easily explained away, including deep vein thrombosis in my left leg, extreme weight loss, bruising, wheezing, and shortness of breath so severe that it was difficult to walk my dog more than a few feet without gasping for air. For...
How Embedding an Algorithm-Based Referral System Into Electronic Health Records Is Increasing Access to Palliative Care
Despite numerous studies showing the benefits of integrating palliative care in both the early- and advanced-stage cancer settings,1 palliative care remains underutilized for most patients with cancer. A recent study by the American Cancer Society found that only 10% of Medicare beneficiaries with...
Belzutifan Achieves Durable Responses Without Surgery in Advanced Pheochromocytoma/Paraganglioma
Belzutifan induced durable responses without surgery in patients with advanced pheochromocytoma or paraganglioma and demonstrated manageable safety in the phase II LITESPARK-015 trial, according to findings presented during the European Society for Medical Oncology (ESMO) Congress 2025 (Abstract...
VT3989 Demonstrates Antitumor Activity and Tolerability in Refractory Mesothelioma
The first-in-class YAP-TEAD inhibitor VT3989 has demonstrated promising antitumor activity and tolerability in patients with refractory mesothelioma, according to findings from a phase I/II trial presented at the European Society for Medical Oncology (ESMO) Congress 2025 (Abstract 920O) and...
First-Line Ribociclib at 400 vs 600 mg in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In a phase II trial (AMALEE) reported in JAMA Oncology, Cardoso et al found that a first-line ribociclib dose of 400 mg was not noninferior to a dose of 600 mg in patients with newly diagnosed hormone receptor–positive, HER2-negative advanced breast cancer. Study Details In the open-label...
Creatine
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Advanced Biliary Tract Cancer: Adding a Polymeric Micellar Paclitaxel to Gemcitabine Plus Cisplatin
Based on the results of the multicenter phase III NEXT trial published by Jeong et al in JAMA Network Open, the addition of a polymeric micellar paclitaxel to standard chemotherapy with gemcitabine plus cisplatin did not improve overall survival in patients with previously untreated advanced...
FANSS: Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?
The results of the multicenter Female Asian Nonsmoker Screening Study (FANSS) suggest that low-dose CT screening is feasible and has value for early lung cancer detection in the historically underserved demographic of Asian women with no history of smoking. These data from the largest United...
PD-1 Inhibitor Approved for Adjuvant Treatment of CSCC
On October 8, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation therapy. C-POST Efficacy was evaluated in C-POST (ClinicalTrials.gov ...
Prior Authorization Is Burdensome for Patients and Results in Treatment Delays, Financial Strain, and Stress, Survey Finds
The process of obtaining insurance prior authorization before a medical procedure, service, or medication prescription has typically been left to clinicians. However, as cancer therapies grow increasingly complex, the burden of navigating insurance prior authorization is increasingly being shared...
In Extensive-Stage Small Cell Lung Cancer, Novel Maintenance Regimen Boosts Overall Survival
The phase Ib DeLLphi-303 trial has reported overall survival data for a novel maintenance regimen in extensive-stage small cell lung cancer following first-line chemoimmunotherapy. Patients treated with the bispecific T-cell engager tarlatamab-dlle plus a PD-L1 inhibitor had a median overall...
Kidney Cancer Cases Expected to Double by 2050
Projected cases of kidney cancer are expected to double by 2050 due to modifiable risk factors, according to findings and estimations published in European Urology. “Kidney cancer is a growing global health problem, and both clinicians and policymakers need to prepare for this steep rise,” stated ...
Oropharyngeal Cancer Quality-of-Life Outcomes: IMRT vs Proton-Beam Therapy
A new phase III clinical trial has found that intensity-modulated radiation therapy (IMRT) and proton-beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. The TORPEdO trial, a randomized study conducted across ...
SABR May Be Comparable to Surgery for Early-Stage NSCLC
Stereotactic radiation therapy (SABR) was found to be noninferior to surgical resection in terms of overall survival for patients with early-stage non–small cell lung cancer (NSCLC), according to 10-year results from the STARS trial presented at the American Society for Radiation Oncology (ASTRO)...
Prostate Cancer: Radiopharmaceutical Plus SBRT Delays Progression in Patients With Limited Metastatic Disease
A new clinical trial found that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation compared with radiation alone. The phase II LUNAR trial is the...
Cancer Deaths Expected to Rise to Over 18 Million in 2050
There has been a rapid increase in the global number of cancer cases and deaths between 1990 and 2023, despite advances in cancer treatment and efforts to tackle cancer risk factors over that same period. Without urgent action and targeted funding, 30.5 million people are forecast to receive a new...
Neoadjuvant FOLFIRINOX vs Gemcitabine-Based Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma
In a Dutch phase III trial (PREOPANC-2) reported in The Lancet Oncology, Janssen et al found no difference in overall survival between patients receiving neoadjuvant FOLFIRINOX vs neoadjuvant gemcitabine-based chemoradiotherapy for resectable or borderline resectable pancreatic ductal...
Can Nicotinamide Reduce the Risk of Skin Cancer Development?
The dietary supplement nicotinamide has been recommended by dermatologists for people with a history of skin cancer since 2015, when a clinical study published by Chen et al in The New England Journal of Medicine including almost 400 participants showed that those who took the vitamin B3 derivative ...
More Tattoos, Lower Risk of Melanoma? New Study Investigates
People with more than one tattoo session may have a decreased risk of developing melanoma—with one key caveat, according to research published by McCarty et al in the Journal of the National Cancer Institute. A team led by Jennifer Doherty, PhD, Huntsman Cancer Institute investigator, Co-Leader of ...
Perioperative Use of Nivolumab With or Without Ipilimumab for Resectable Diffuse Pleural Mesothelioma
Perioperative use of nivolumab with or without ipilimumab may prove to be of benefit for patients with resectable diffuse pleural mesothelioma, according to the findings of a phase II study published in Nature Medicine. Findings from the study were also presented during the International...
